We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Lipid Micelles May Replace Viruses for Gene Therapy

By Biotechdaily staff writers
Posted on 17 Apr 2006
Researchers have synthesized a lipid molecule with an exceptionally large, branched, and electrically charged head group that facilitates transfection of mammalian cells with genetic material and which may replace the use of viruses for this purpose.

Currently, engineered viruses are used as the vehicle for gene transplantation in more than 70% of clinical trials. More...
Another method, using DNA-lipid micelles, avoids problems of immune responses to the viral agent but is only being tested in about 10% of clinical trials. The main reason for this has been the lower efficiency of the micelles as compared to the viral vectors.

Investigators at the University of California, Santa Barbara (USA), have added a novel lipid molecule to the pool available for synthesis of DNA-lipid micelles. The molecule contains a highly charged (16+) multivalent cationic lipid, MVLBG2, with a large, highly branched nanoscale head group. The unusually large head group allows "honeycomb” interaction between the lipid and DNA molecules.

The investigators used their lipid-DNA micelles to transfect two lines of mouse and two lines of human tissue culture cells. One of the lines was comprised of mouse embryonic fibroblasts (MEF) that are notoriously difficult to transfect.

Results published in the March 29, 2006, issue of the Journal of the American Chemical Society revealed that the honeycomb structure of the lipid head group greatly enhanced the micelle's ability to transfer genetic material to the target cell. Senior author Dr. Cyrus R. Safinya, professor of molecular, cellular, and developmental biology at the University of California, Santa Barbara, said, Our data confirm that MEFs are generally hard to transfect. And the new molecule is far superior for transfection of these cells as compared to commercial lipids.”




Related Links:
University of California, Santa Barbara

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.